Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Fulgent Genetics (NASDAQ:FLGT) announced its quarterly earnings results on Friday. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14, FiscalAI reports. Fulgent Genetics had a negative net margin of 13.62% and a negative return on equity of 2.55%. The company had revenue of $83.34 million for the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics updated its FY 2026 guidance to -1.450–1.450 EPS.

Here are the key takeaways from Fulgent Genetics’ conference call:

• The company’s largest customer is moving substantial testing in‑house, cutting expected 2026 revenue from that customer from $70.8M in 2025 to about $11.8M, creating a front‑loaded revenue and margin headwind in H1 2026.
• Fulgent agreed to acquire Bako Diagnostics and StrataDx for roughly $55.5–$56M, which management expects to add about $50–$55M of revenue, expand the anatomic pathology salesforce, and materially reduce customer concentration if the deals close in March 2026.
• Management emphasized technology gains — an in‑house digital pathology/image management platform (EasyoPath) and multiple AI modules are now deployed, which they say is improving throughput, quality and long‑term operating leverage.
• Therapeutic pipeline progress: FID‑007 completed Phase 2 enrollment (46 patients) with encouraging early efficacy/safety and is targeting an FDA interaction in mid‑2026 and potential Phase 3 start in 2027, while FID‑022 is advancing through dose escalation.
• Financial picture is mixed — 2025 revenue grew 14% to $322.7M and beat non‑GAAP EPS guidance, but Q4 GAAP loss widened to $23.4M, adjusted EBITDA turned negative, and 2026 guidance forecasts ~$350M revenue with a non‑GAAP EPS loss of $1.45 and wider operating losses due to acquisition, R&D and sales investments.

Fulgent Genetics Trading Down 38.1%

Fulgent Genetics stock traded down $9.43 during midday trading on Friday, hitting $15.33. The stock had a trading volume of 2,610,665 shares, compared to its average volume of 222,404. The company has a market capitalization of $473.85 million, a PE ratio of -11.03 and a beta of 0.86. Fulgent Genetics has a 52-week low of $14.57 and a 52-week high of $31.04. The firm’s fifty day moving average is $25.66 and its two-hundred day moving average is $24.83.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on FLGT shares. Piper Sandler raised their price target on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Wall Street Zen downgraded Fulgent Genetics from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $36.00 target price on shares of Fulgent Genetics in a research report on Friday, November 14th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Fulgent Genetics presently has a consensus rating of “Hold” and a consensus target price of $32.00.

Fulgent Genetics News Summary

Here are the key news stories impacting Fulgent Genetics this week:

• Positive Sentiment: Q4 EPS beat consensus, reporting $0.16 vs. estimates near $0.02–$0.03 — a clear near‑term earnings upside that shows some operational strength. Zacks: Q4 Earnings Top Estimates
• Positive Sentiment: Company issued FY‑2026 revenue guidance of $350M, which is roughly above/near consensus (~$343.6M) and signals revenue growth expectations as the business mix shifts. Seeking Alpha: Forecasts $350M 2026 Revenue
• Neutral Sentiment: Management highlighted acquisitions (Bako, StrataDx) that are reshaping the customer mix — these can drive revenue scale over time but bring integration expense and timing uncertainty. Seeking Alpha: Acquisitions Reshape Customer Mix
• Neutral Sentiment: Q4 revenue was $83.34M, a modest miss vs. analyst expectations (~$85M), and the company reported negative net margin and ROE — mixed operating metrics that temper the EPS beat. MarketBeat: Q4 Results & Transcript
• Negative Sentiment: The principal negative: FY‑2026 EPS guidance of about -$1.45 is far below the consensus estimate (~- $0.59), signaling a much larger expected loss than analysts anticipated — the main driver of the sharp selloff. Seeking Alpha: Guidance Details
• Negative Sentiment: Market commentary and coverage note the guidance shock and integration/expense risk as reasons for the heavy share decline; coverage pieces summarize why the stock pulled back sharply after the release. AAII: Why FLGT Stock Is Down

Insider Transactions at Fulgent Genetics

In other news, COO Jian Xie sold 1,140 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total value of $32,296.20. Following the transaction, the chief operating officer directly owned 336,749 shares in the company, valued at $9,540,099.17. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Hanlin Gao sold 1,075 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total transaction of $30,454.75. Following the sale, the insider directly owned 952,890 shares of the company’s stock, valued at approximately $26,995,373.70. This trade represents a 0.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 31.76% of the stock is owned by company insiders.

Institutional Trading of Fulgent Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of FLGT. Amundi boosted its holdings in shares of Fulgent Genetics by 289.2% in the first quarter. Amundi now owns 34,316 shares of the company’s stock valued at $583,000 after purchasing an additional 25,500 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Fulgent Genetics by 28.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock worth $3,428,000 after buying an additional 45,279 shares in the last quarter. Legal & General Group Plc grew its holdings in Fulgent Genetics by 14.1% during the 2nd quarter. Legal & General Group Plc now owns 21,025 shares of the company’s stock worth $418,000 after acquiring an additional 2,599 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Fulgent Genetics by 2.4% during the second quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after purchasing an additional 785 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in Fulgent Genetics by 8.0% during the 2nd quarter. American Century Companies Inc. now owns 52,168 shares of the company’s stock valued at $1,037,000 after acquiring an additional 3,860 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.